Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 975
countries
28
conditions
2 106

8 trials match your criteria

Desmoplastic small round cell tumour

Recruiting

Study of lurbinectedin and irinotecan in adults and young adults with advanced desmoplastic small round cell tumor

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lurbinectedin

Small cell lung cancer metastatic

Not recruiting

Study of Lurbinectedin and Pembrolizumab for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lurbinectedin

Neoplasm malignant

Not recruiting

Study of Lurbinectedin and Irinotecan for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan

Small cell lung cancer metastatic

Not recruiting

Study of Lurbinectedin and Atezolizumab in Patients with Advanced Small Cell Lung Cancer Who Have Previously Received Platinum Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Endometrial cancer recurrent

Not recruiting

Study on the Safety and Effectiveness of Lurbinectedin and Dostarlimab for Patients with Advanced Endometrial Cancer After Platinum-based Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab

Small cell lung cancer extensive stage

Not recruiting

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Small cell lung cancer

Not recruiting

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan

Leiomyosarcoma metastatic

Not recruiting

Study of Lurbinectedin and Doxorubicin for First-line Treatment in Patients with Metastatic Leiomyosarcoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Filgrastim

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.